Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of ...

Pfizer shares were lower on Tuesday despite third-quarter financial results that came in ahead of expectations. Sales of a ...

Market Catalysts host Julie Hyman takes a closer look at some of the trending tickers during Tuesday's trading session.

Pfizer stock dipped early Tuesday despite hiking its 2025 profit guidance, as third-quarter sales and earnings both toppled ...

Pfizer (NYSE: PFE) beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 ...

Pfizer also has set its sights on becoming a giant in oncology, and to support this, completed the acquisition of Seagen in 2023. Two of Seagen's products in the most recent quarter delivered ...

Shares in data analytics software developer Palantir tumble even as the company tops analysts' earnings estimates.

U.S. stock futures declined early Tuesday following a rally driven by artificial intelligence (AI) optimism. Futures on the Nasdaq 100 (NDX), the ...

Drugmaker Pfizer ($PFE) is set to report its Q3 earnings results on November 4 before the market opens. Analysts are ...

Global pharmaceutical company Pfizer (NYSE:PFE) in Q3 CY2025, but sales fell by 5.9% year on year to $16.65 billion. On the ...

Metsera stock bidding war intensifies as Novo and Pfizer race to secure next-gen obesity drug assets amid surging market ...

Pfizer is a cheap stock by most metrics. It trades at a price-to-earnings multiple of only 13, while the S&P 500 average is ...